28Dec
24Dec
Legally Blind Boy Given the Gift of Sight, Just in Time for Christmas
Angelo Yu, 8, loves to read but the 2nd grader has to hold books right up to his face. That's because he is legally blind, the side effect of a brain tumor. Now, the young boy has gotten the best Christmas gift he could ask for, thanks to tech expert Katie Linendoll and her sister, Nadine, an oncology nurse practitioner. Angelo’s gift arrived in a large box, a pair of electronic glasses called eSight. Read more >>
23Dec
Productive Liaisons — Bringing Together Industry and Academia
Boston Harbor Angel members, Ziad Moukheiber and David Powsner, are the hosts of Failure – the Podcast, a podcast about about business failures, focusing on startups and emerging companies. In episode five, Moukheiber and Powsner chat with Randall Wright, program director of the MIT Industrial Liaison Program. Wright shares his unique view of creativity and innovation in business and research. Tune in >>
23Dec
New technology helps Odessa man with sight problems
A former Odessa High School student who is now attending college in Austin is not letting visual impairment get in his way. In fact, thanks to new technology Nick Flores' world has been opened up right before his eyes. Nick has optic nerve atrophy (ONA) which causes his vision to be distorted and affects depth perception. Fortunately Nick recently learned of a new device called eSIGHT, which has changed the way he sees everything. Read more >>
21Dec
iCons Works at Fall Workshop
About 100 iCons scholars and applicants gathered in the Integrative Learning Center of UMass Amherst on Nov 9, 2017 for the annual iCons Fall Integrative Workshop. They came to hear Dr. Jonathan Thon tell the story of how his start-up company Platelet Biogenesis came to be. Integrated Concentration in Science (iCons) Program Director Justin Fermann introduced Thon to the crowd, telling the iCons students “we are here because we have work to do, and he’s got some problems we need...
20Dec
Corbus Readies Pivotal Phase 3 Trial of Anabasum, Possible Scleroderma Treatment
Corbus Pharmaceuticals is planning a global Phase 3 trial to assess anabasum (JBT-101) as a treatment for scleroderma. If successful, the company plans to apply to regulatory authorities, asking that anabasum be the first specifically approved treatment for scleroderma. Read more >>
20Dec
New Jersey Gym Gives Gift Of Sight To Legally Blind Boy For Christmas
A legally blind boy is getting the gift of sight this Christmas thanks to a New Jersey gym. Read more >>
15Dec
Boston Harbor Angels Awards Portfolio Companies at Annual Meeting
Boston Harbor Angels, one of the top three elite angels groups in the US, recognized three portfolio companies at its annual end-of-year general meeting. Exit of the Year Award: Corbus Pharmaceuticals on NASDAQ Biotech Startup of the Year Award: Astrocytes Pharmaceuticals Inc. IT Startup of the Year Award: Wasabi The meeting featured interviews with Yuval Cohen, CEO of Corbus Pharmaceuticals and Mark Tepper, President & Chief Scientific Officer of Corbus Pharmaceuticals; and David Friend, CEO and co-founder of Wasabi. The group also honored Mic Williams,...
15Dec
Predictions 2018: How GDPR is Forcing Big Changes in Storage
Experts believe we might see things like machine-learning-assisted storage and de-archiving becoming commonplace during the coming calendar year. Read more >>
15Dec